You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
UK 14,304 tartrate
Biological Activity for UK 14,304 tartrate
UK 14,304 tartrate is a water-soluble form of UK 14,304 (Cat. No. 0425). Full α2 adrenergic agonist. Centrally active following systemic administration in vivo.
Technical Data for UK 14,304 tartrate
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for UK 14,304 tartrate
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for UK 14,304 tartrate
The following data is based on the product molecular weight 442.23. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||4.52 mL||22.61 mL||45.23 mL|
|2.5 mM||0.9 mL||4.52 mL||9.05 mL|
|5 mM||0.45 mL||2.26 mL||4.52 mL|
|25 mM||0.09 mL||0.45 mL||0.9 mL|
Product Datasheets for UK 14,304 tartrate
References for UK 14,304 tartrate
References are publications that support the biological activity of the product.
Cambridge (1981) UK-14,304, a potent and selective alpha2-gonist for the characterisation of alpha-adrenoceptor subtypes. Eur.J.Pharmacol. 72 413 PMID: 6115759
Andorn et al (1988) Specific [3H]UK-14,304 binding in human cortex occurs at multiple high affinity states with α2-adrenergic selectivity and different affinities for GTP. Life Sci. 43 1805 PMID: 2904634
Macdonald et al (1997) Gene targeting - homing in on α2-adrenoceptor-subtype function. TiPS 18 211 PMID: 9227000
Chopin et al (1999) Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxyDA lesions of the nigrostriatal pathway. J.Pharmacol.Exp.Ther. 288 798 PMID: 9918591
If you know of a relevant reference for UK 14,304 tartrate, please let us know.
View Related Products by Product Action
Keywords: UK 14,304 tartrate, UK 14,304 tartrate supplier, Water-soluble, α2-Adrenergic, alpha2-Adrenergic, Receptors, α2-adrenoceptor, alpha2-adrenoceptors, a2-adrenoceptor, a2-adrenergic, UK14304, tartrate, Adrenergic, Alpha-2, 2466, Tocris Bioscience
1 Citation for UK 14,304 tartrate
Citations are publications that use Tocris products. Selected citations for UK 14,304 tartrate include:
Harris et al (2018) Dorsal BNST α2A-Adrenergic Receptors Produce HCN-Dependent Excitatory Actions That Initiate Anxiogenic Behaviors. J Neurosci 38 8922 PMID: 30150361
Do you know of a great paper that uses UK 14,304 tartrate from Tocris? Please let us know.
Reviews for UK 14,304 tartrate
There are currently no reviews for this product. Be the first to review UK 14,304 tartrate and earn rewards!
Have you used UK 14,304 tartrate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.